UK Mounjaro warning issued ahead of heatwave temperatures
The last year has seen a huge increase in the number of people taking GLP-1 receptor agonists, some prescribed by the NHS and others by private doctors, with common injectibles including semaglutide (Wegovy and Ozempic), tirzepatide (Mounjaro) and liraglutide (Saxenda).
As the temperatures rise, experts are stressing that users must store weight loss injections in a refrigerator (2-8°C or 36-46°F), especially after starting the course.
Review your ICB's local policy about treating patients with tirzepatide (Mounjaro) for weight management in a primary care setting and visit: https://t.co/03msJjjTU9 pic.twitter.com/tHs6lyJHc4 — We are Primary Care (@PrimaryCareNHS) June 12, 2025
'Weight loss injections can be adversely affected by hot weather, particularly regarding storage and stability," says James O'Loan, obesity specialist and weight loss injection expert at pharmacists Chemist4U.
"Understanding the storage instructions when using any prescribed medication is vital to keep it in optimal condition.
"Although weight loss injections can be stored at room temperature for up to 30 days (some injections are 42 days, so always check with your prescriber or refer to the patient information leaflet), this is only provided the temperature does not exceed 30°C. During hot weather, and to be on the safe side, it is always best to keep your weight loss injections refrigerated if you're able."
Can I take my Mounjaro pen on holiday?
The advice for the UK heatwave is also also worth noting for those heading on holiday or travelling during the warmer weather.
However, if you're flying, remember to pack your injections in your carry-on since the baggage hold on a plane can plummet to below-freezing temperatures.
Finding the right temperature for your pen is important: not too hot or too cold. If you inject after incorrectly storing your pen, it might not be safe for use.
How do I know if my Mounjaro pen is safe to use?
"There are a few important things to consider when checking if your weight loss pen is safe to use," says James.
"Inspect the pen to ensure it is not damaged and the medicine inside is clear, with no particles or cloudiness. The liquid should be colourless or slightly yellow. If you have left your pen unrefrigerated during hot weather and are unsure whether it is still safe to use, always consult your prescriber before injecting.
"Staying hydrated whilst taking weight loss injections is key. Weight loss injections can cause side effects such as nausea, constipation, diarrhoea and dizziness, which, without sufficient fluids, can lead to dehydration.
"We recommend drinking plenty of water throughout the day, even when you're not thirsty. If experiencing diarrhoea or vomiting, try using electrolyte drinks, rehydrate quickly and apply sunscreen whenever you are outdoors. This will help those who suffer from heightened sensitivity to UV rays.'
Do you need to tell your travel insurance you are taking Mounjaro?
Yes. Travel insurance providers are warning that the growing number of Brits turning to these breakthrough drugs for weight management could lose their cover and face huge medical bills abroad if they don't declare their usage when arranging travel insurance.
Many don't want to admit they are taking the weight-loss drugs, or think that if they buy it privately, it doesn't need to be declared.
Niraj Mamtora, director at Forum Insurance, says: 'Weight-loss medications like Ozempic are transforming lives across the UK, but too many travellers don't realise the insurance implications. If you're using these drugs, you must declare both the medication and the condition it's prescribed for.
'Failure to do so is not a minor oversight - it's a serious breach of your travel insurance contract. If you need medical help overseas and haven't declared your medication, your claim can be refused and your policy cancelled. The financial consequences can be severe.'
Recommended reading:
What happens if you don't disclose weight-loss jabs on your travel insurance?
'Non-disclosure is a gamble that's simply not worth taking," says Niraj.
"If you don't declare your medication or the underlying condition, your insurer is within their rights to refuse any claim, even if it seems unrelated.
'Many travellers only discover too late that their travel insurance claims are rejected, leaving them without support and facing potentially huge bills.
"With the average medical claim abroad now exceeding £1,700, and costs rising significantly with age, being properly covered is more important than ever.'
Insurance claims related to undeclared conditions or medications can be refused, even if the issue seems unrelated.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
22 minutes ago
- The Guardian
UK sickle cell patients ‘get worse care than sufferers of similar disorders'
People living with sickle cell disease face substandard care as its treatment significantly lags behind advances relating to other genetic disorders such as cystic fibrosis, a report has found. The study, commissioned by the NHS Race and Health Observatory and carried out by researchers at Imperial College London, analysed various measures of care for sickle cell disease between 2010 and 2024, including clinical trials, approved drugs and reviews of existing studies. The findings indicated that sickle cell care across the UK does not have parity with other genetic disorders, such as cystic fibrosis, with there being only 0.5 specialist nurses per 100 patients for sickle cell, compared with two per 100 for cystic fibrosis. The report also found that there is 2.5 times more research funding for cystic fibrosis than for sickle cell, meaning the former has more treatment options and breakthrough drugs than the latter. Evidence of substandard care for people with sickle cell was also found, with 20% of babies with the condition not being seen by a specialist by three months of age, despite the NHS screening programme guidelines that 90% of babies should be seen by this milestone. Prof Habib Naqvi, the chief executive of the observatory, said sickle cell care 'significantly lags behind' that for other rare genetic conditions. He added: 'These inequalities are stark and, despite being a common genetic disorder, sickle cell has endured years of inadequate attention and investment that has resulted in the experiences we then see play out for people living with the condition. 'We do highlight the stark inequalities that exist for people with sickle cell in comparison with other rare conditions, but we also offer evidence-based solutions for meaningful change.' The report also found that these disparities in care for people with sickle cell disease were not due to a lack of need, given that hospital admissions for sickle cell rose by 42% between 2013 and 2022. These disparities exist despite the fact sickle cell disease is just as prevalent as other rare genetic disorders. The disorder primarily affects people from an African-Caribbean background. In England, about 17,000 people are living with the disease, an inherited blood disorder, with 250 new cases a year. Sickle cell disease changes the shape of blood cells into crescents, hindering blood flow. People with the condition experience severe painful episodes, which can require hospital admission. Approximately 11,000 people in the UK have cystic fibrosis, a condition which causes breathing and digestive problems due to mucus. The median age of death for sickle cell is 47. For cystic fibrosis, it is 48. John James, the chief executive of the Sickle Cell Society, said the landmark report 'makes it impossible for anyone to ignore the existence of deep inequalities faced by people with sickle cell – in healthcare, research funding and wider recognition'. He added that the findings were sobering. 'It is unimaginable that these disparities have, beyond all reason, continued for so long. 'However, by analysing how other long-term conditions are supported and resourced, it is clear to see the tangible difference that investment in healthcare makes.' Prof Bola Owolabi, NHS England's director for the National Healthcare Inequalities Improvement Programme, said: 'It is unacceptable that people with sickle cell disease face worse outcomes than those with other conditions, which is why the NHS England has stepped up with its sickle cell and thalassemia quality improvement project. 'Patient care has also been boosted by introduction of digital care plans so they don't need to repeat their stories to healthcare staff, and we have launched a campaign to boost awareness of key signs and symptoms of the disorder called Can You Tell It's Sickle Cell?'
Leader Live
3 hours ago
- Leader Live
Alzheimer's drugs rejected for NHS because benefits ‘too small' to justify cost
The National Institute for Health and Care Excellence (Nice) is standing by its earlier decision to turn down donanemab and lecanemab after considering new information submitted by manufacturers. Charities described the decision as 'disappointing' and a 'painful setback' for patients, while the firms Lilly, which makes donanemab, and Eisai, which makes lecanemab, said they would appeal. Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer's. They represent a huge step forward in research because they target a known cause of the disease, rather than just treating symptoms. Both drugs bind to amyloid, a protein which builds up in the brains of people living with Alzheimer's disease. By binding to amyloid, the drugs are designed to help clear the build-up and slow down cognitive decline. Publishing its final draft guidance, Nice said the treatments have been shown to delay progression from mild to moderate Alzheimer's by four to six months. But it said the medicines cannot be provided on the NHS because they are not good value for money and 'only provide modest benefits at best'. Last year, NHS England published a briefing paper suggesting the cost of bringing the drugs to the health service could be £500 million to £1 billion per year. Professor Fiona Carragher, Alzheimer's Society's chief policy and research Officer, said the decision was 'disappointing'. She said: 'There is no doubt that today's decision is a setback for people with Alzheimer's disease. 'It is highly disappointing that we are in a situation where treatments that slow the progression of the condition are not available on the NHS. 'The reality we're faced with is that these treatments remain out of reach of both the NHS and most eligible people with Alzheimer's disease. 'In other diseases like cancer, treatments have become more effective, safer and cheaper over time. It's essential we see similar progress in dementia. 'The fact is, even if donanemab and lecanemab were made available on the NHS tomorrow, too many patients wouldn't be able to access them because the health system isn't ready to deliver them. 'The science is flying but the system is failing.' She said the Government must now commit to 'the long-term investment needed to fundamentally change dementia diagnosis so that we are ready for new treatments', including bringing in earlier diagnosis and access to specialist diagnostic tests. She added: 'We are heading towards a future where disease-slowing treatments reduce the devastating impact of dementia, and we cannot afford to delay preparing the NHS for them.' Hilary Evans-Newton, chief executive of Alzheimer's Research UK, said: 'This rejection is a painful setback for people affected by Alzheimer's – but sadly not a surprising one. 'The drugs' modest benefits, combined with the significant costs of delivering them in the NHS, meant they faced insurmountable challenges. 'People with early Alzheimer's in England and Wales now face a long wait for innovative new treatments as they won't be able to access lecanemab or donanemab unless they can afford to pay privately. 'This decision sends a troubling signal to the life sciences sector – undermining confidence in the UK as a home for research, innovation and clinical trials. That risks lasting damage to both patients and the economy. 'Nice's decision should ring alarm bells for a Government that, only a year ago, pledged to make the UK a global leader in dementia treatments. 'With over 30 Alzheimer's drugs now in late-stage trials globally, momentum is building – and more will enter regulatory systems in the years ahead. 'Without intervention from Government, people with Alzheimer's will continue to miss out — not because science is failing, but because the system is.' Helen Knight, director of medicines evaluation at Nice, said: 'While we recognise the hope these treatments offer, the evidence shows they only provide modest benefits at best and substantial resources would be needed to provide them. 'The committee accepted that any slowing of the disease getting worse would be meaningful for people with mild cognitive impairment or mild dementia caused by Alzheimer's disease and their carers because it could mean more time socialising, driving and being independent, so needing less help day-to-day from family members. 'But the committee concluded the small benefits to patients shown in the clinical trials and the lack of long-term evidence of effectiveness balanced with the substantial resources the NHS would need to commit to the treatments would be too great and could displace other essential treatments and services that deliver substantial benefits to patients. 'We have done everything we possibly can to try and achieve a positive outcome in our assessments of these treatments, including providing an additional opportunity for evidence to be submitted. 'We realise today's news will be disappointing for many, but we now need to focus on the encouraging pipeline of new Alzheimer's drugs in development, a number of which are already earmarked for Nice evaluation.' Drug firms and registered patient groups now have until July 8 to appeal against the decision. In clinical trials, donanemab, which is given via a drip, has been shown to slow the rate at which memory and thinking get worse by more than 20%. Results also suggest the drug leads to a 40% slowing in the decline of everyday activities such as driving, enjoying hobbies and managing money. Lecanemab – also administered via drip – has been shown to successfully remove protein build-up from the brains of people living with early Alzheimer's disease. For people taking lecanemab, this meant the decline in their thinking and memory skills was slowed down by 27%. It also slowed down the decline in quality of life by up to 56%. However, side-effects of the drugs can be serious, including brain bleeds and risk of death. A reformulation of lecanemab is being developed so it can be administered subcutaneously under the skin. Nice could then review the drug in this form. Lilly said it would appeal the Nice decision on the grounds it was unreasonable based on the evidence submitted. Chris Stokes, president and general manager of UK and Northern Europe at Lilly, said: 'If the system can't deliver scientific firsts to NHS patients, it is broken. 'If the Government is to deliver on its goals to reduce lives lost to the biggest killers and put Britain at the forefront of transforming treatment for dementia, it must keep pace with licensed medical breakthroughs.' Dr Jeremy Isaacs, national clinical director for dementia at NHS England, said: 'NHS England has a dedicated team preparing for the rollout of new Alzheimer's treatments. 'There are several other Alzheimer's treatments in development, and the NHS stands ready to offer patients access to new treatments as soon as they are deemed by regulators to be clinically and cost effective.'
North Wales Chronicle
3 hours ago
- North Wales Chronicle
Alzheimer's drugs rejected for NHS because benefits ‘too small' to justify cost
The National Institute for Health and Care Excellence (Nice) is standing by its earlier decision to turn down donanemab and lecanemab after considering new information submitted by manufacturers. Charities described the decision as 'disappointing' and a 'painful setback' for patients, while the firms Lilly, which makes donanemab, and Eisai, which makes lecanemab, said they would appeal. Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer's. They represent a huge step forward in research because they target a known cause of the disease, rather than just treating symptoms. Both drugs bind to amyloid, a protein which builds up in the brains of people living with Alzheimer's disease. By binding to amyloid, the drugs are designed to help clear the build-up and slow down cognitive decline. Publishing its final draft guidance, Nice said the treatments have been shown to delay progression from mild to moderate Alzheimer's by four to six months. But it said the medicines cannot be provided on the NHS because they are not good value for money and 'only provide modest benefits at best'. Last year, NHS England published a briefing paper suggesting the cost of bringing the drugs to the health service could be £500 million to £1 billion per year. Professor Fiona Carragher, Alzheimer's Society's chief policy and research Officer, said the decision was 'disappointing'. She said: 'There is no doubt that today's decision is a setback for people with Alzheimer's disease. 'It is highly disappointing that we are in a situation where treatments that slow the progression of the condition are not available on the NHS. 'The reality we're faced with is that these treatments remain out of reach of both the NHS and most eligible people with Alzheimer's disease. 'In other diseases like cancer, treatments have become more effective, safer and cheaper over time. It's essential we see similar progress in dementia. 'The fact is, even if donanemab and lecanemab were made available on the NHS tomorrow, too many patients wouldn't be able to access them because the health system isn't ready to deliver them. 'The science is flying but the system is failing.' She said the Government must now commit to 'the long-term investment needed to fundamentally change dementia diagnosis so that we are ready for new treatments', including bringing in earlier diagnosis and access to specialist diagnostic tests. She added: 'We are heading towards a future where disease-slowing treatments reduce the devastating impact of dementia, and we cannot afford to delay preparing the NHS for them.' Hilary Evans-Newton, chief executive of Alzheimer's Research UK, said: 'This rejection is a painful setback for people affected by Alzheimer's – but sadly not a surprising one. 'The drugs' modest benefits, combined with the significant costs of delivering them in the NHS, meant they faced insurmountable challenges. 'People with early Alzheimer's in England and Wales now face a long wait for innovative new treatments as they won't be able to access lecanemab or donanemab unless they can afford to pay privately. 'This decision sends a troubling signal to the life sciences sector – undermining confidence in the UK as a home for research, innovation and clinical trials. That risks lasting damage to both patients and the economy. 'Nice's decision should ring alarm bells for a Government that, only a year ago, pledged to make the UK a global leader in dementia treatments. 'With over 30 Alzheimer's drugs now in late-stage trials globally, momentum is building – and more will enter regulatory systems in the years ahead. 'Without intervention from Government, people with Alzheimer's will continue to miss out — not because science is failing, but because the system is.' Helen Knight, director of medicines evaluation at Nice, said: 'While we recognise the hope these treatments offer, the evidence shows they only provide modest benefits at best and substantial resources would be needed to provide them. 'The committee accepted that any slowing of the disease getting worse would be meaningful for people with mild cognitive impairment or mild dementia caused by Alzheimer's disease and their carers because it could mean more time socialising, driving and being independent, so needing less help day-to-day from family members. 'But the committee concluded the small benefits to patients shown in the clinical trials and the lack of long-term evidence of effectiveness balanced with the substantial resources the NHS would need to commit to the treatments would be too great and could displace other essential treatments and services that deliver substantial benefits to patients. 'We have done everything we possibly can to try and achieve a positive outcome in our assessments of these treatments, including providing an additional opportunity for evidence to be submitted. 'We realise today's news will be disappointing for many, but we now need to focus on the encouraging pipeline of new Alzheimer's drugs in development, a number of which are already earmarked for Nice evaluation.' Drug firms and registered patient groups now have until July 8 to appeal against the decision. In clinical trials, donanemab, which is given via a drip, has been shown to slow the rate at which memory and thinking get worse by more than 20%. Results also suggest the drug leads to a 40% slowing in the decline of everyday activities such as driving, enjoying hobbies and managing money. Lecanemab – also administered via drip – has been shown to successfully remove protein build-up from the brains of people living with early Alzheimer's disease. For people taking lecanemab, this meant the decline in their thinking and memory skills was slowed down by 27%. It also slowed down the decline in quality of life by up to 56%. However, side-effects of the drugs can be serious, including brain bleeds and risk of death. A reformulation of lecanemab is being developed so it can be administered subcutaneously under the skin. Nice could then review the drug in this form. Lilly said it would appeal the Nice decision on the grounds it was unreasonable based on the evidence submitted. Chris Stokes, president and general manager of UK and Northern Europe at Lilly, said: 'If the system can't deliver scientific firsts to NHS patients, it is broken. 'If the Government is to deliver on its goals to reduce lives lost to the biggest killers and put Britain at the forefront of transforming treatment for dementia, it must keep pace with licensed medical breakthroughs.' Dr Jeremy Isaacs, national clinical director for dementia at NHS England, said: 'NHS England has a dedicated team preparing for the rollout of new Alzheimer's treatments. 'There are several other Alzheimer's treatments in development, and the NHS stands ready to offer patients access to new treatments as soon as they are deemed by regulators to be clinically and cost effective.'
